All Research on Oncology in Asia-Pacific

Insight

Report
Report

Epidemiology of Hepatocellular Cancer in China

The size of HCC patient population in China provides a lucrative market for anti-cancer drugs. This epidemiologic analysis uses historical cancer incidence data to estimate and forecast HCC patient populations in China between 2012 and 2030.

Published By Datamonitor
$2800
Buy
Report
Report

Hepatocellular cancer: Nexavar & Pipeline products

Nexavar is pursuing line extensions to tighten its grip on the HCC treatment market

Published By Datamonitor
$2000
Buy
Report
Report

Pipeline: Colorectal Cancer

Developers look to other molecular targets to avoid direct competition

Published By Datamonitor
$2800
Buy

View all Insight >>

Market Data

Interactive Model
Interactive Model

Medtrack: Cancer Pipeline Databook - May 2013

This in-depth Excel databook covers the cancer pipeline by company and phase.

Published By Datamonitor
$2900
Buy
Interactive Model
Interactive Model

The Prostate Cancer Market Forecast to 2021

Recent approvals reinvigorate mCRPC market

Published By Datamonitor
$6400
Buy
Interactive Model
Interactive Model

Market Forecasts: Non-Small Cell Lung Cancer

There are 700,000 new cases of lung cancer each year and NSCLC constitutes about 80% of the total lung cancer patient population. Pharma have been attracted by the high incidence of this disease and the NSCLC pipeline has grown substantially.

Published By Datamonitor
$6400
Buy

Profiles

Company Profile
Company Profile

Kyowa Hakko Kirin Co., Ltd.

Kyowa Hakko Kirin (KHK or 'the group') is a Japan-based provider of pharmaceuticals and bio-chemicals. The group is a subsidiary of Kirin Holdings Company, which holds 50.1% of KHK's shares. The group is headquartered in Tokyo, Japan, and employed 7,152 people as on December 31, 2013.

Published By MarketLine
$175
Buy
Company Profile
Company Profile

Chugai Pharmaceutical Co., Ltd.

Chugai Pharmaceutical Co., Ltd. (Chugai or 'the company'), the Japanese subsidiary of the Roche Group, is engaged in biopharmaceutical research and development. It produces antibody drugs primarily focusing on oncology, renal diseases and bone and joint diseases. The company operates in Europe, the Americas and Asia Pacific. It is headquartered in Tokyo, Japan, and employed 6,872 people as of December 31, 2013.

Published By MarketLine
$175
Buy
Company Profile
Company Profile

Nippon Kayaku Co., Ltd.

Nippon Kayaku (or 'the company') is engaged in various businesses, including pharmaceuticals, functional chemical products, color chemicals, inflators, and catalysts. The company primarily operates in Asia, North America and Europe. It is headquartered in Tokyo, Japan, and employed 4,619 people as of May 31, 2013.

Published By MarketLine
$175
Buy

View all Profiles >>

No help is available.